The Group's principal
activity is to conduct molecular diagnosis for the early detection and
treatment of cancer and other complex diseases. The Group's products
based on DNA methylation, which are aimed at making early detection and
treatment easier, more accurate and more convenient for the patient.
Group compares patient's cells against healthy and sick reference
which enables an exact diagnosis of disease at a very early stage and
physicians with essential information to help guide the appropriate
The group operates in Europe and North America.